Patents by Inventor Bruno Lina

Bruno Lina has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Biomarkers For Early Determination Of Severity Of Influenza Related Disease
    Publication number: 20190076484
    Abstract: The present invention relates to the use of at least one biomarker for predicting the severity of a disease caused by the infection of an individual with an influenza virus, wherein said biomarker is selected in a group comprising (i) the alpha diversity value of the microbiome present in a respiratory sample of said individual and (ii) the microbiome profile of the said respiratory sample.
    Type: Application
    Filed: September 23, 2016
    Publication date: March 14, 2019
    Applicants: Universite Claude Bernard Lyon 1, Hospices Civils de Lyon, University of Washington
    Inventors: Laurence Josset, Maxime Pichon, Bruno Lina, Michael Katze, Stanley Langevin
  • PAR-4 ANTAGONISTS FOR USE IN THE TREATMENT OR PREVENTION OF INFLUENZA VIRUS TYPE A INFECTIONS
    Publication number: 20160095897
    Abstract: The present invention provides methods and compositions (such as pharmaceutical compositions) comprising PAR4 antagonists for treating or preventing influenza virus type A infections, in particular H1N1 infection. PAR4 antagonists may be combined with a PAR2 agonist or a PAR1 antagonist.
    Type: Application
    Filed: April 22, 2014
    Publication date: April 7, 2016
    Inventors: Beatrice RITEAU, Ba Vuong LE, Bruno LINA
  • Sulphated arabinogalactans, apiogalacturonans and sulphated heteroglycans for treating diseases caused by the influenza virus
    Patent number: 9011939
    Abstract: The present invention relates to polysaccharides selected from sulphated arabinogalactans, apiogalacturonans and sulphated heteroglycans intended to be used as a drug for the preventive or curative treatment of an influenza virus, as well as to the pharmaceutical compositions including, in particular in combination with at least one pharmaceutically acceptable carrier: either an extract of Codium fragile, including sulphated arabinogalactans, or an extract of Zostera marina or Lemna minor, including apiogalacturonans, or an extract of Caulerpa racemosa, including sulphated heteroglycans.
    Type: Grant
    Filed: January 3, 2012
    Date of Patent: April 21, 2015
    Assignees: Elicityl, Centre National de la Recherche Scientifique, Insititut National de la Sante et de la Recherche Medicale—I.N.S.E.R.M., Commissariat a l'Energie Atomique et aux Energies Alternatives (CEA)
    Inventors: Bruno Lina, Olivier Ferraris, Ho Hong Hai Vo, François-Loïc Cosset, Judit Szecsi, Alain Heyraud, Hugues Lortat-Jacob, Julia Bartoli, Rabia Sadir, Thierry Livache, Benoît Darblade, Stéphane Havet, Silvère Bonnet
  • HPIV-2 variants and their medical applications
    Patent number: 8927701
    Abstract: A variant phylogenetic group of HPIV-2, more particularly a novel variant phylogenetic sub-group of HPIV-2, and a means for diagnosing HPIV-2 which take into account this novel group and this novel sub-group.
    Type: Grant
    Filed: July 18, 2008
    Date of Patent: January 6, 2015
    Assignees: Centre National de la Recherche Scientifique, Les Hospices Civils de Lyon
    Inventors: Bruno Lina, Olivier Terrier, Danielle Françoise Thouvenot
  • SULPHATED ARABINOGALACTANS, APIOGALACTURONANS AND SULPHATED HETEROGLYCANS FOR TREATING DISEASES CAUSED BY THE INFLUENZA VIRUS
    Publication number: 20140023675
    Abstract: The present invention relates to polysaccharides selected from sulphated arabinogalactans, apiogalacturonans and sulphated heteroglycans intended to be used as a drug for the preventive or curative treatment of an influenza virus, as well as to the pharmaceutical compositions including, in particular in combination with at least one pharmaceutically acceptable carrier: either an extract of Codium fragile, including sulphated arabinogalactans, or an extract of Zostera marina or Lemna minor, including apiogalacturonans, or an extract of Caulerpa racemosa, including sulphated heteroglycans.
    Type: Application
    Filed: January 3, 2012
    Publication date: January 23, 2014
    Applicants: Elicityl, Commissariat A L'Energie Atomique Et Aux Energies Alternatives (CEA), Institut National De La Sante Et De La Recherche Medicale - I.N.S.E.R.M., Centre National De La Recherche Scientifique
    Inventors: Bruno Lina, Olivier Ferraris, Ho Hong Hai Vo, Francois-Loic Cosset, Judit Szecsi, Alain Heyraud, Hugues Lortat-Jacob, Julia Bartoli, Rabia Sadir, Thierry Livache, Benoit Darblade, Stephane Havet, Silvére Bonnet
  • HPIV-2 VARIANTS AND THEIR MEDICAL APPLICATIONS
    Publication number: 20110077170
    Abstract: A variant phylogenetic group of HPIV-2, more particularly a novel variant phylogenetic sub-group of HPIV-2, and a means for diagnosing HPIV-2 which take into account this novel group and this novel sub-group.
    Type: Application
    Filed: July 18, 2008
    Publication date: March 31, 2011
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, LES HOSPICES CIVILS DE LYON
    Inventors: Bruno Lina, Olivier Terrier, Danielle Francoise Thouvenot